Modified albumin-bilirubin predicted survival of unresectable hepatocellular carcinoma patients treated with immunotherapy

Table 5 Predictors of overall survival in unresectable hepatocellular carcinoma patients who received atezolizumab plus bevacizumab therapy

Variables	Univariate		Multivariate
	Hazard ratio (95%CI)	P value	Adjusted hazard ratio (95%CI)	P value
Age	1.00 (0.97-1.02)	0.970	0.99 (0.96-1.02)	0.540
Male sex	1.15 (0.51-2.60)	0.740	0.97 (0.41-2.28)	0.940
ECOG-PS
0	1.00 (Reference)
1	2.03 (0.62-6.66)	0.240
Presence of cirrhosis
No	1.00 (Reference)
Yes	2.19 (0.53-9.13)	0.280
Etiology of disease
NASH	0.70 (0.32-1.52)	0.360
Viral hepatitis	1.48 (0.73-2.97)	0.280
Alcohol	2.09 (0.81-5.39)	0.130
BCLC stage
B	1.00 (Reference)
C	0.66 (0.33-1.31)	0.230
Extrahepatic metastasis
No	1.00 (Reference)
Yes	0.70 (0.37-1.32)	0.270
Portal invasion
No	1.00 (Reference)
Yes	1.29 (0.68-2.47)	0.440
AFP > 500 ng/mL	1.26 (0.67-2.36)	0.480
CTP class
A	1.00 (Reference)
B	5.38 (2.66-10.89)	< 0.001	2.63 (1.19-5.78)	0.020
mALBI grade
1 + 2a	1.00 (Reference)
2b + 3	5.20 (2.52-10.76)	< 0.001	3.90 (1.71-8.90)	0.001
Prior treatment for HCC
No	1.00 (Reference)
Yes	0.87 (0.42-1.78)	0.700
Prior local therapy for HCC
No	1.00 (Reference)
Yes	0.79 (0.39-1.58)	0.500
Prior systemic therapy for HCC
No	1.00 (Reference)
Yes	1.80 (0.79-4.11)	0.160
Combination of AB and local treatment as first-line treatment
No	1.00 (Reference)
Yes	0.05 (0.01-27.12)	0.340

AB: Atezolizumab plus bevacizumab; AFP: Alpha fetoprotein; BCLC: Barcelona Clinic Liver Cancer; CI: Confidence interval; CTP: Child-Turcotte-Pugh; ECOG-PS: Eastern Cooperative Oncology Group Performance Status; HCC: Hepatocellular carcinoma; mALBI: Modified albumin-bilirubin; NASH: Nonalcoholic steatohepatitis.